NCT04334044

Treatment of SARS Caused by COVID-19 With Ruxolitinib

Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Grupo Cooperativo de Hemopatías Malignas · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In December 2019, a new virus emerged in Wuhan, China rapidly becoming a pandemic with registered cases above 800,000 around the world. The virus is now known as SARS-CoV2 calling its disease coronavirus-19 or COVID-19. The mortality of the virus has been reported around 2-10% and its causes because of the proinflammatory immune response generated on the host. The cytokines involved in the immune response to COVID-19 are IL-1, IL-2, IL4, IL-6, IL-10, IL-12, IL-13, IL-17, GCSF, MCSF, IP-10, MCP-1, MIP-1α, HGF, IFN-γ y TNF-α. Ruxolitinib is an inhibitor of JAK 1/2 which is responsable for multiple cellular signals including the proinflammatory IL-6. Ruxolitinib works as and immunomodulator decreasing the cytotoxic T lymphocytes and increasing the Treg cells. This study is intended to stop the disregulated immune response caused by COVID-19 that generates the pneumonia and subsequent severe acute respiratory syndrome.

Conditions

• COVID-19
• Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

Type	Name	Description
DRUG	Ruxolitinib Oral Tablet	Ruxolitinib 5 mg twice a day

Timeline

• Start date: 2020-09-01
• Primary completion: 2021-04-12
• Completion: 2021-04-30
• First posted: 2020-04-03
• Last updated: 2021-07-07

Locations

1 site across 1 country: Mexico